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With respect to cervical cancer management, Finland and the
Netherlands are comparable in relevant characteristics, e.g., fertil-
ity rate, age-of-mother at first birth and a national screening pro-
gramme for several years. The aim of this study is to compare
trends in incidence of and mortality from cervical cancer in
Finland and the Netherlands in relation to the introduction and in-
tensity of the screening programmes. Therefore, incidence and
mortality rates were calculated using the Cancer Registries of Fin-
land and the Netherlands. Data on screening intensity were
obtained from the Finnish Cancer Registry and the Dutch evalua-
tion centre at ErasmusMC-Rotterdam. Women aged 30–60 have
been screened every 5 years, in Finland since 1992 and in the
Netherlands since 1996. Screening protocols for smear taking and
referral to the gynaecologist are comparable. Incidence and mor-
tality rates have declined more in Finland. In 2003, age-adjusted
incidence and mortality in Finland were 4.0 and 0.9 and in the
Netherlands 4.9 and 1.4 per 100,000 woman-years, respectively.
Excess smear use in the Netherlands was estimated to be 24 per
1,000 women during a 5-year interval compared to 121 in Finland.
The decline in mortality in Finland seems to be almost completely
related to the screening programme whereas in the Netherlands it
was initially considered to be a natural decline. Differences in risk
factors might also play a role: the Netherlands has higher popula-
tion density and higher percentages of immigrants and (female)
smokers. The greater excess smear use in Finland might also have
affected incidence.
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Mass screening for cervical cancer has been performed in sev-
eral countries with varying success, depending on the coverage
and intensity of screening such as intervals between screens, age
groups covered, attendance rate, quality of follow-up after a posi-
tive smear, coordination of organized and opportunistic screening
(screening outside the screening programme) and other character-
istics.1-3 Actual proof of the effectiveness of cervical cancer
screening was never obtained from randomized cervical cancer
screening trials; instead, the evidence of the efficacy and effective-
ness is based on cohort follow-up studies and also on geographical
correlation studies.4,5 Consequently, debate has arisen on the con-
tribution of screening to the decrease in cervical cancer mortality
that was found in some areas as well as to the prevention of an
increase in other areas where cervical cancer mortality did not
change significantly despite extensive screening.1,6,7 The objective
of cervical cancer screening is to prevent the occurrence of inva-
sive cancer and thus death by detecting and treating high-grade
intraepithelial lesions, being precursors of invasive cancer. The
most widely used screening approach to detect lesions has been
cervical cytology, followed by investigation of ‘‘positive’’ women
with colposcopy and directed biopsy.4,8 Addition of an HPV test
to the screening programme or substitution of the cytological test
by the HPV-DNA test and even the inclusion of HPV vaccination
in the national vaccination programmes are now under considera-
tion in several countries with mass screening programmes.9-14
It is now well-established that HPV infection is the central
causal factor in cervical cancer. HPV is a common sexually trans-
mitted infection and both women and men are usually exposed to
the virus after the onset of sexual intercourse. The risk of infection
with HPV and also the risk of cervical cancer is increased by the
number of sexual partners, age at first intercourse and sexual
behavior of the woman’s male partners.15,16 Additional risk indi-
cators for cervical cancer are the number of live births, long-term
use of oral contraceptives, cigarette smoking and immunosuppres-
sion.16 The incidence of cervical cancer varies across the world
depending on the presence of the above-mentioned risk factors
and the availability of a screening programme.17
The aim of the present study was to compare trends in the inci-
dence of cervical cancer in Finland and the Netherlands and to
relate the trends to the extent and intensity of the screening pro-
grammes. Finland and the Netherlands are comparable in most
other relevant characteristics, e.g. gross domestic product, fertility
rate and age at first birth.18,19
Material and methods
Study population
Age-specific and age-adjusted world standardized rates (WSR)
for cervical cancer incidence and mortality were calculated from
the Finnish Cancer Registry (FCR) and the Netherlands Cancer
Registry (NCR).
The FCR is a population-based nationwide cancer registry
established in 1952, registration began in 1953. The FCR receives
data on cancer cases from hospitals, health centres, medical practi-
tioners and pathological and cytological laboratories. It also
receives information about all death certificates which mention
cancer. The file of all deaths occurring in Finland is checked annu-
ally against the files of the FCR.
Nine regional cancer registries submit their data to the NCR,
which has been a population-based nationwide cancer registry
since 1989. Registration in the Netherlands began in the region of
the Eindhoven Cancer Registry in 1955 and was followed by the
other regions during the 1980s. Notification is obtained from the
Pathology Departments, the Dutch Network and National database
for Pathology (PALGA), and Hematology Departments. Other
sources are the Radiotherapy Departments of the hospitals, as well
as the National Registry of Hospital Discharge Diagnosis, which
accounts for up to 8% of new cases apparently without pathologi-
cal notification.20 Death certificates are not available in an identifi-
able form to the regional cancer registries and the NCR. Data on
deaths from cervical cancer were therefore derived from Statistics
Netherlands.21
In the NCR, carcinoma in situ of the cervix is not registered;
accordingly, also for Finland only cases of invasive cervical can-
cer were included in this study.
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Mapping
Maps were made based on truncated age-adjusted (World
Standard) incidence rates per 100,000 women. For cities with
>100,000 inhabitants the rates were shown as such as circles on
the maps. The radius of the circle indicates the size of the popula-
tion and the color the WSR. The remaining rates were smoothed
to prevent disturbing chance variation.22 Smoothing was done by
calculating a weighted average of the age-adjusted incidence rates
of the neighboring areas for each grid (size 2 km by 2 km) to
define the color of that grid. The weights were inversely associated
with the distance and reached 50% at a distance of 25 km and zero
at 150 km. Every step between the categories represents a 1.13-
fold increase in the rate.
History of screening programmes
In 1963 an organized cervical screening programme with 5-year
intervals was introduced as a pilot project in 3 municipalities in
Finland, extending to most parts of the country within a few years.
By 1970, the coverage of the invitational programme already
exceeded 80% of women in the target age group of 30–50 years.
Later, in 1992 30–60 years became the national target age. Some
municipalities also invited women 25–30 and/or 60–65 years old.
Furthermore, from the early 1970s onwards, registered coverage
has become almost complete. According to a bylaw drawn up in
1992 the municipalities had to offer cervical cancer screening to
30- to 60-year-old women with a 5-year screening interval.23
In the Netherlands, cytological screening has been available to
women in some regions of the Netherlands since the mid 1970s
within a combination of opportunistic screening and local and re-
gional invitational programmes, with 3-year intervals.24 In 1988, a
nationwide screening programme was initiated aimed at women
aged 35–54 years screened at 3-year intervals.25 In 1996 screening
activities were restructured for a new national programme. From
then on women between 30 and 60 years old were screened at
5-year intervals, leaving the number of 7 invitations during a life-
time unchanged.26
Screening practices
In the Finnish screening programme, smears are taken out by
trained nurses (midwives) in local health care centres and the
smears are screened by cytotechnicians. Smear quality is under
continuous control and assessed by the cytology laboratories. The
cytologist checks every abnormal smear and a proportion of
normal smears.23 Referral to the gynaecologist for colposcopy and
biopsy takes place after a clear finding of dysplasia (Pap III-V) or
after several borderline findings (Pap II), based on the recommen-
dation of the cytologist (Table I).
In the Netherlands, most of the programme smears are taken in
general practice, by general practitioners or their practice assis-
tants. Investigation of the smears is performed by specially trained
cytotechnicians. The nonnegative cases are evaluated by a head-
cytotechnician. A cytopathologist has the final supervision and
writes the final report on the nonnegative cases. Screening results
are filed at the laboratories and in PALGA. Comparable to Fin-
land, referral to the gynaecologist takes place after repeated bor-
derline findings (Pap II or IIIA) or after finding positive cytology
(Pap IIIB-V).
Participation
In Finland the participation rate exceeded 70% (72% in 2004)
but in addition to the organized screening programme, opportunis-
tic smears are also more common. It has been estimated that the
coverage of smears during a 5-year period was about 90% (i.e. at
least 1 smear made per female) and the coverage of women with a
Pap-smear at least once in their lifetime was estimated to be
98%.23 Opportunistic screening is estimated to be more than
100% of the total screening activity (i.e. the use of smears is
2 times higher than recommended by the programme) and the
excess use of Pap smears (all smears taken in a certain period that
do not contribute to the observed coverage of the target popula-
tion) was 121 per 1,000 women in a 5-year period.2,23
In the Netherlands the participation rate was about 65%.29 At
the end of 1996, together with opportunistic screening, the
percentage of women 30–60 years old with at least 1 smear in the
previous 5 years was 80% and coverage of women with a Pap-
smear at least once in their lifetime was 90%.26 However, partici-
pation in each following round of the population-based screening
programme became lower; furthermore and with increasing age,
attendance declined, being 10–15% lower for the age group 50–59
than the age group 30–49.30,31 The excess use of Pap smears was
very low: 24 per 1,000 women in a 5-year period with opportunis-
tic screening being <2% of the total screening activity in 2003.2,29
Results
During the period 1955–1964, the incidence of invasive cervical
cancer in Finland was 15 per 100,000 woman-years, age-adjusted
to the world standard population, with a slightly increasing trend
within that period (Fig. 1). From 1965 to 1990 incidence rapidly
decreased to 2.8 per 100,000 woman-years in 1991, which gives
an overall decrease of 70–80%. After 1991, the incidence
increased to 4.0 per 100,000 woman-years in 2003. The mean age-
specific incidence rate for the age group 25–39 increased from 2.1
in 1989–1994 to 4.6 in 1998–2003; it was higher in urbanized
areas (Fig. 2a). Mortality from cervical cancer decreased continu-
ously from 6.8 per 100,000 woman-years during 1958–1962 to 0.9
per 100,000 woman-years in 2003 (Fig. 3).
In the Netherlands, the incidence of cervical cancer varied from
18 to 12 per 100,000 woman-years, age-adjusted to the world
standard population, in the period 1960–1970 (Eindhoven registry)
(Fig. 1). In 1970 incidence started to decrease from 12 per
100,000 woman-years (Eindhoven registry) to 3.6 per 100,000
woman-years in 2003 (national rates: 4.9 per 100,000). The mean
age-specific incidence rate in the Netherlands for the age group
25–39 decreased from 11.6 in the period 1989–1994 to 9.8 in the
period 1998–2003 with higher incidences in the cities and more
urbanized areas (Fig. 2b). These differences were bigger than in
TABLE I – COMPARISON OF PAP SMEAR CLASSIFICATION AND
BETHESDA SYSTEM
WHO terminology Pap score27 Bethesda28
Atypical cells Pap II ASCUS/AGUS
Mild/moderate dysplasia Pap IIIA LSIL
Severe dysplasia Pap IIIB HSIL
Carcinoma-in-situ Pap IV HSIL/AIS
Squamous cell carcinoma/
Adenocarcinoma
Pap V Squamous cell
carcinoma/
adenocarcinoma
FIGURE 1 – Age-adjusted (world standard) incidence rates per
100,000 women in Finland and the Netherlands, according to year of
diagnosis.
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Finland. Mortality from cervical cancer in the Netherlands
decreased from 5.4 per 100,000 woman-years in 1970 to the low-
est rate ever, 1.1 per 100,000 woman-years, in 2002 (Fig. 3).
Discussion
There is worldwide evidence of a considerable decline in inci-
dence and mortality from cervical cancer in areas with active mass
screening programmes. However, the effectiveness of these pro-
grammes varies, and initially the trends in the disease were hardly
affected by screening in some countries such as the United King-
dom and Scotland.1 This study has shown similarities, but also dif-
ferences in the trends in incidence of and mortality from cervical
cancer between Finland and the Netherlands. In Finland, the 80%
decrease in the incidence and mortality rates has mainly resulted
from the national screening programme, even though wide-spread
opportunistic screening could also have affected these rates but in
a clearly less degree.5,23,32,33 Changes in sexual behavior probably
increased rather than decreased the background risk.34 Mortality
in the Netherlands started to decrease in 1970, earlier than an
effect of mass screening could be expected, but definitely contin-
ued to drop after the introduction of screening, being currently
40% lower than around 1960. A drop in the incidence of cervical
cancer and a shift towards diagnosis of invasive cervical cancer in
a less advanced stage seems the best explanation for the ‘‘natural’’
decline.35,36 In Finland, the death records have been continuously
linked with the incidence records on an individual level. In the
Netherlands, unfortunately there is no linkage of the cancer regis-
try with the cause-of-death registry. However after 1970, there
FIGURE 2 – (a) Truncated age-adjusted (world standard) incidence rates per 100,000 women in Finland, age group 25–39 years, in the period
1989–1994 (left) and the period 1998–2003 (b) Truncated age-adjusted (world standard) incidence rates per 100,000 women in the Netherlands,
age group 25-39 years, in the period 1989–1994 (left) and the period 1998–2003.
FIGURE 3 – Age-adjusted (world standard) mortality rates per
100,000 women in Finland and the Netherlands, according to year of
death.
1856 VAN DER AA ET AL.
were very few uterus NOS cases of cancer in the Netherlands and
therefore the trends in mortality were affected negligibly.21 Differ-
ences in mortality rates may also partly be explained by a differ-
ence in background incidence between Finland and the Nether-
lands, the latter having more urbanized areas and more migration
from abroad than Finland. These migrant women originate mainly
from countries with higher cervical cancer incidence rates, the
WSR per 100,000 women in 2002 being 12 for Morocco, 16 for
Indonesia, 13 for women from the Caribbean islands to even 27
for Suriname37,38; 4% of all cervical cancer cases in the Nether-
lands are diagnozed in immigrant women.39
Part of the difference in the decrease of incidence of cervical
cancer could be explained by risk factors for cervical cancer. In
contrast to Finland, the Netherlands does have a very high popula-
tion density in most of the country and a higher percentage of
(female) smokers, both of which are risk factors for cervical can-
cer.21 Furthermore, the fertility rate was higher, especially in cath-
olic parts of the Netherlands up until 1970.21
In Finland, a recent increase was observed in the incidence of
cervical cancer in young women, possibly related to changes in
sexual behavior during the last few decades, suggesting an
increasing role of some potentially oncogenic sexually transmitted
infections, such as HPV.21,34 Also among young Finnish women
smoking increased during the 1980s. In the Netherlands, an increase
in the incidence of cervical cancer could not yet be observed.40 How-
ever, HIV and other sexually transmitted infections have been
increasing, according to the latest surveillance data.41
In both countries, discussion has started on a Quadrivalent
Human Papillomavirus (Types 6, 11, 16, 18) Recombinant vac-
cine, which has been approved in the EU for prescription to
women aged 9 years and older, to include it in the vaccination
programmes to reduce further (and definitely) the incidence of cer-
vical and other HPV-related cancers.9,12,42 However, follow-up
studies of the vaccines on the effect on cancer risk, i.e. the problems
and limitations of the vaccine, are not available. Furthermore,
vaccination may create a false feeling of complete protection. The
screening programme therefore may need to be continued in addi-
tion to the vaccination for several decades more.
The percentages of hysterectomy found for both countries might
also explain the difference in incidence rates. Hysterectomy has
been under discussion since the 1970s because of regional and
international variations in frequency, indications and surgical
methods.43 In some countries, the increasing frequency of hyster-
ectomy has led to an underestimation of the actual risk for cervical
cancer. A study from Finland calculated 11% higher hysterec-
tomy-corrected rates than the uncorrected rates.43 The prevalence
of hysterectomy in Finland in 1987–1989 was approximately the
same as in the Netherlands. However, from 1991 to 1999 the
annual number of hysterectomies in Finland increased by 16% and
decreased by 24% in the Netherlands in almost the same
period.43,44 Therefore, the adjustment for age-specific fractions of
women with a hysterectomy may have had some influence on the
cervical cancer rates in both countries: the corrected incidence
rates for Finland being somewhat higher and for the Netherlands
somewhat lower.
To conclude, incidence and mortality rates of cervical cancer
rates became very low in both Finland and the Netherlands, in fact
the lowest in Europe due to a large extent their mass screening
programmes. In the Netherlands, there still seems to be some
room for improvement, whereas Finland might need to pay more
attention to young women and the high rate of excess smear use.
As long as cervical cancer occurs in women who are screened,
most attention must be directed toward minimizing false-negative
smears. Furthermore, anxiety might be caused in women by
repeated testing of low-grade cervical abnormalities and colpo-
scopic evaluation of high-grade abnormalities.4,45 Unfortunately,
more intensive screening greatly increases the need for more
interventions for lesions which would never have developed
into tumors.46 Attention to quality of life and potential adverse
aspects should therefore be part of the evaluation of screening
programmes.
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